Skip to Content
Merck
CN
  • Contact sensitization to methylisothiazolinone in Finland--a multicentre study.

Contact sensitization to methylisothiazolinone in Finland--a multicentre study.

Contact dermatitis (2010-12-21)
Leena Ackermann, Kristiina Aalto-Korte, Kristiina Alanko, Taina Hasan, Riitta Jolanki, Kaija Lammintausta, Antti Lauerma, Arja Laukkanen, Jussi Liippo, Riitta Riekki, Anna-Maija Vuorela, Tapio Rantanen
ABSTRACT

Antimicrobials constitute the second most common cause of contact allergy to cosmetics. Methylisothiazolinone (MI), previously always used together with methylchloroisothiazolinone (MCI), has recently been approved in the EU for use on its own in cosmetics and also various industrial products. MCI has been classified as an extreme-strong and MI as a strong-moderate sensitizer. To study the frequency of positive patch test reactions to MI, and its relevance and relation to MCI/MI sensitivity, in Finland. Over a period of 3 years (2006-2008), MI 0.1% (1000 ppm) and 0.03% (300 ppm) were patch tested in 10,821 patients at eight Finnish dermatological clinics. During 2008, patients with positive reactions to MI were asked to take part in a repeated open application test (ROAT). Of the patients tested, 1.4% and 0.6% showed positive patch test reactions to 0.1% and 0.03% MI, respectively. Sixty-six per cent of those who were MI-positive were also positive to 100 ppm MCI/MI. Thirty-three agreed to undergo the use test, and 10 of these gave positive results (30%). Our data show that MI used alone also potentially induces contact allergy. Careful monitoring is needed to determine whether or not this antimicrobial is safe to use in cosmetics.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Methyl-4-isothiazolin-3-one hydrochloride, ≥99%
Supelco
2-Methyl-4-isothiazolin-3-one, analytical standard
Sigma-Aldrich
2-Methyl-4-isothiazolin-3-one, 95%